IRIS Accounts Production v24.3.2.46 04222016 director 1.6.23 31.5.24 31.5.24 0 0 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh042220162023-05-31042220162024-05-31042220162023-06-012024-05-31042220162022-05-31042220162022-06-012023-05-31042220162023-05-3104222016ns15:EnglandWales2023-06-012024-05-3104222016ns14:PoundSterling2023-06-012024-05-3104222016ns10:Director12023-06-012024-05-3104222016ns10:PrivateLimitedCompanyLtd2023-06-012024-05-3104222016ns10:SmallEntities2023-06-012024-05-3104222016ns10:AuditExempt-NoAccountantsReport2023-06-012024-05-3104222016ns10:SmallCompaniesRegimeForDirectorsReport2023-06-012024-05-3104222016ns10:SmallCompaniesRegimeForAccounts2023-06-012024-05-3104222016ns10:AbridgedAccounts2023-06-012024-05-3104222016ns10:RegisteredOffice2023-06-012024-05-3104222016ns5:CurrentFinancialInstruments2024-05-3104222016ns5:CurrentFinancialInstruments2023-05-3104222016ns5:Non-currentFinancialInstruments2024-05-3104222016ns5:Non-currentFinancialInstruments2023-05-3104222016ns5:ShareCapital2024-05-3104222016ns5:ShareCapital2023-05-3104222016ns5:RetainedEarningsAccumulatedLosses2024-05-3104222016ns5:RetainedEarningsAccumulatedLosses2023-05-3104222016ns5:PlantMachinery2023-06-012024-05-31042220161ns10:Director12023-05-31042220161ns10:Director12022-05-31042220161ns10:Director12023-06-012024-05-31042220161ns10:Director12022-06-012023-05-31042220161ns10:Director12024-05-31042220161ns10:Director12023-05-31
REGISTERED NUMBER: 04222016 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MAY 2024

FOR

VASCULAR AND THROMBOSIS EXPERTS LIMITED

VASCULAR AND THROMBOSIS EXPERTS LIMITED (REGISTERED NUMBER: 04222016)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2024




Page

Company Information 1

Abridged Balance Sheet 2

Notes to the Financial Statements 3


VASCULAR AND THROMBOSIS EXPERTS LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 MAY 2024







DIRECTOR: Prof C N McCollum





REGISTERED OFFICE: The Lodge
858 Wilmslow Road
Didsbury
Manchester
M20 2AU





REGISTERED NUMBER: 04222016 (England and Wales)





ACCOUNTANTS: Wyatt Morris Golland Ltd
Park House
200 Drake Street
Rochdale
Lancashire
OL16 1PJ

VASCULAR AND THROMBOSIS EXPERTS LIMITED (REGISTERED NUMBER: 04222016)

ABRIDGED BALANCE SHEET
31 MAY 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 27,625 34,479
Investments 5 29,026 35,725
56,651 70,204

CURRENT ASSETS
Debtors 466,041 399,447
Cash at bank 128 7,543
466,169 406,990
CREDITORS
Amounts falling due within one year 189,699 65,062
NET CURRENT ASSETS 276,470 341,928
TOTAL ASSETS LESS CURRENT
LIABILITIES

333,121

412,132

CREDITORS
Amounts falling due after more than one year (14,167 ) (24,167 )

PROVISIONS FOR LIABILITIES (7,026 ) (8,910 )
NET ASSETS 311,928 379,055

CAPITAL AND RESERVES
Called up share capital 5 5
Retained earnings 311,923 379,050
SHAREHOLDERS' FUNDS 311,928 379,055

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 May 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 May 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

All the members have consented to the preparation of an abridged Income Statement and an abridged Balance Sheet for the year ended 31 May 2024 in accordance with Section 444(2A) of the Companies Act 2006.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 22 December 2024 and were signed by:



Prof C N McCollum - Director


VASCULAR AND THROMBOSIS EXPERTS LIMITED (REGISTERED NUMBER: 04222016)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2024

1. STATUTORY INFORMATION

Vascular and Thrombosis Experts Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 25% on reducing balance and 20% on cost

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2023 - NIL).

4. TANGIBLE FIXED ASSETS
Totals
£   
COST
At 1 June 2023 76,933
Additions 2,506
At 31 May 2024 79,439
DEPRECIATION
At 1 June 2023 42,454
Charge for year 9,360
At 31 May 2024 51,814
NET BOOK VALUE
At 31 May 2024 27,625
At 31 May 2023 34,479

VASCULAR AND THROMBOSIS EXPERTS LIMITED (REGISTERED NUMBER: 04222016)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MAY 2024

5. FIXED ASSET INVESTMENTS

Information on investments other than loans is as follows:
Totals
£   
COST OR VALUATION
At 1 June 2023 56,850
Additions 30,000
Revaluations (6,699 )
At 31 May 2024 80,151
PROVISIONS
At 1 June 2023 21,125
Charge for year 30,000
At 31 May 2024 51,125
NET BOOK VALUE
At 31 May 2024 29,026
At 31 May 2023 35,725

Cost or valuation at 31 May 2024 is represented by:
Totals
£   
Valuation in 2021 12,768
Valuation in 2022 2,572
Valuation in 2023 (4,610 )
Valuation in 2024 (6,699 )
Cost 76,120
80,151

6. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 31 May 2024 and 31 May 2023:

2024 2023
£    £   
Prof C N McCollum
Balance outstanding at start of year (6,566 ) 769,943
Amounts advanced 277,684 -
Amounts repaid 6,566 (776,509 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 277,684 (6,566 )

Interest is charged monthly on advances to directors at a rate of 2.25%

7. RELATED PARTY DISCLOSURES

During the year, total dividends of £280,000 were paid to the director .

During the year the company traded with companies controlled by the director and a balance of £52,189 (2023: £14,560) is included in trade debtors. The company also had loan accounts with companies controlled by the director and had lent funds to a shareholder. The amounts outstanding at the year end are included in other debtors and amount to £101,593 (2023: £384,708)